Open AccessJournal Article
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers
Susan H. Wei,Chuan-Mu Chen,Gordon Strathdee,Jaturon Harnsomburana,Chi-Ren Shyu,Farahnaz Rahmatpanah,Huidong Shi,Shu Wing Ng,Pearlly S. Yan,Kenneth P. Nephew,Robert S. Brown,Tim H M Huang +11 more
TL;DR: It is suggested that a higher degree of CpG island methylation is associated with early disease recurrence after chemotherapy, and this degree is potentially useful as epigenetic markers for predicting treatment outcome in ovarian cancer patients.
read more
Abstract: Purpose: The purpose of this study was to profile methylation alterations of CpG islands in ovarian tumors and to identify candidate markers for diagnosis and prognosis of the disease.
Experimental Design: A global analysis of DNA methylation using a novel microarray approach called differential methylation hybridization was performed on 19 patients with stage III and IV ovarian carcinomas.
Results: Hierarchical clustering identified two groups of patients with distinct methylation profiles. Tumors from group 1 contained high levels of concurrent methylation, whereas group 2 tumors had lower tumor methylation levels. The duration of progression-free survival after chemotherapy was significantly shorter for patients in group 1 compared with group 2 ( P < 0.001). Differential methylation in tumors was independently confirmed by methylation-specific PCR.
Conclusions: The data suggest that a higher degree of CpG island methylation is associated with early disease recurrence after chemotherapy. The differential methylation hybridization assay also identified a select group of CpG island loci that are potentially useful as epigenetic markers for predicting treatment outcome in ovarian cancer patients.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
TL;DR: ASS1 silencing in HCC cell lines is associated with simultaneous cisplatin resistance and ADI-PEG 20 sensitivity which suggests a promising combination therapeutic strategy for the management of HCC.
Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis
Ie Ming Shih,Li Chen,Chen Wang,Jinghua Gu,Ben Davidson,Leslie Cope,Robert J. Kurman,Jianhua Xuan,Tian Li Wang +8 more
TL;DR: The findings support the view that low- grade and high-grade serous carcinomas are distinctly different with low-grade, but not high- grade, serious carcinomas that are related to serous borderline tumor and cystadenoma.
57
Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.
Dirk Bauerschlag,Ole Ammerpohl,K. Bräutigam,Christian Schem,Qiong Lin,Marion T. Weigel,Felix Hilpert,Norbert Arnold,Nicolai Maass,Ivo Meinhold-Heerlein,Wolfgang Wagner +10 more
TL;DR: Global analysis of DNA methylation patterns might reveal specific CpG sites that correlate with progression-free interval (PFI) after therapy in ovarian cancer, and such analysis might be of prognostic value.
55
Epigenetic therapy for the treatment of epithelial ovarian cancer: A clinical review.
TL;DR: This review discusses the common epigenetic changes that occur in epithelial ovarian cancer, the current epigenetic therapies that may target these changes, and the clinical experience with epigenetic therapy for the treatment of epithelium ovarian cancer.
54
Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy.
Anne P G Crijns,Evelien W. Duiker,S de Jong,Pax H.B. Willemse,A.G.J. van der Zee,E.G.E. de Vries +5 more
TL;DR: An overview of the current status of prognostic marker and molecular targeting research in ovarian cancer, including microarray studies, is presented and the potential of specific tumor-targeted therapy, based on expression of a prognostic tumor profile, may be of interest.
54
References
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
TL;DR: The use of MSP is demonstrated to identify promoter region hypermethylation changes associated with transcriptional inactivation in four important tumor suppressor genes (p16, p15, E-cadherin and von Hippel-Lindau) in human cancer.
6.1K
Cancer statistics, 2001.
TL;DR: Estimates of the number of new cancer cases and deaths expected in the US in the current year and the most recent data on cancer incidence, mortality, and survival reveal large disparities in cancer incidence and mortality across racial/ethnic groups.
3.5K
Cancer-epigenetics comes of age
Peter A. Jones,Peter W. Laird +1 more
TL;DR: Current mechanistic understanding of the role of DNA methylation in malignant transformation is reviewed, and it is suggested Knudson's two–hit hypothesis should be expanded to include epigenetic mechanisms of gene inactivation.
2.5K
Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer
Stephen B. Baylin,Manel Esteller,Michael R. Rountree,Kurtis E. Bachman,Kornel E. Schuebel,James G. Herman +5 more
TL;DR: In the translational arena, the promoter hypermethylation changes hold great promise as DNA tumor markers and their potentially reversible state creates a target for cancer therapeutic strategies involving gene reactivation.
•Journal Article
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
TL;DR: DAC could have a role in increasing the efficacy of chemotherapy for patients whose tumors lack MLH1 expression because of hMLH1 promoter methylation, and is consistent with loss of MMR having no effect on sensitivity in vitro to Taxol.
531
Related Papers (5)
Joseph F. Costello,Joseph F. Costello,Michael C. Frühwald,Michael C. Frühwald,Dominic J. Smiraglia,Laura J. Rush,Gavin P. Robertson,Xin Gao,Fred A. Wright,Jamison D. Feramisco,Päivi Peltomäki,James C. Lang,David E. Schuller,Li Yu,Clara D. Bloomfield,Michael A. Caligiuri,Allan J. Yates,Ryo Nishikawa,H.-J. Su Huang,Nicholas J. Petrelli,Xueli Zhang,M. S. O'Dorisio,William A. Held,Webster K. Cavenee,Webster K. Cavenee,Christoph Plass +25 more